Tarsus Pharmaceuticals, Inc. — Director's Dealing 2021

Jan 8, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Tarsus Pharmaceuticals, Inc. (TARS)
CIK: 0001819790
Period of Report: 2021-01-07

Reporting Person: Neervannan Seshadri (Chief Operating Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-01-07	Stock Option (right to buy)	$47.25	A	61499	Acquired	2031-01-06	Common Stock (61499)	Direct

Footnotes

F1: 25% of the option shares shall vest on January 7, 2022, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years.